Transgene is using two companion tests, one being developed by Beckman Coulter and another by Ventana Medical Systems, to pick best responders to its investigational non-small cell lung cancer drug TG4010.

The immunohistochemistry test developed by Ventana will allow Transgene to identify patients expressing mucin 1-positive tumor cells in clinical trials. TG4010 was designed to target MUC1, and the IHC assay will be used to select patients to be enrolled in an upcoming Phase IIb/III trial for the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.